but it might increase the risk of non-approval to a small degree. Dont you think it reduces risk rather than increasing it?
If the risk of approval is in the newness of the platform, I can easily see a risk-averse FDA delaying approval. OTOH, an advisory panel given the proper data including the EU approval and followup would more likely approve with an appropriate risk management plan.
Market Data 
Markets 
AI
